ORPHA:354
GM1 gangliosidosis
Also known as: Beta-galactosidase-1 deficiency · GLB1 deficiency · Landing disease
Publications
4,909
Trials
9
Interventional, condition-specific
Researchers
1,308
Distinct authors in sample
Gene link
GLB1
Definitive
Readiness
6/6
Stages with a signal
Clinical definition (Orphanet)
GM1 gangliosidosis is a rare lysosomal storage disorder characterized biochemically by deficient beta-galactosidase activity and clinically by a wide range of variable neurovisceral, ophthalmological and features.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018149
- MeSH:D016537
- UMLS:C0085131
- NCIT:C84739
Additional Mondo synonyms (3)
GM>1< gangliosidosis · Landing syndrome · gangliosidosis GM1
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
6/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — GLB1
- LiteraturePresent
4,909 matched papers (2,765 in last 10 years) Source
- Phenotype characterisedPresent
238 HPO annotations (e.g. Intrauterine growth retardation; Mild intellectual disability; Dystonia) Source
- Animal modelPresent
4 genotype models (Mus musculus) Source
- Orphan designationPartial
4 EMA designations (none yet with FDA orphan-indication approval) — e.g. nizubaglustat Source
- Interventional trialPresent
9 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (GLB1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
238
Associated phenotypes · MONDO:0018149
- Intrauterine growth retardation
- Mild intellectual disability
- Dystonia
- Hepatomegaly
- Hypoplastic acetabulae
Showing 5 of 238 — open Monarch for the full list.
Animal models (Monarch / Alliance)
4
Model associations linked to this Mondo ID
- Glb1tm1Adz/Glb1tm1Adz [background:] involves: 129/Sv * C57BL/6·MGI:3581423·Mus musculus
- Glb1tm1Adz/Glb1tm1Adz [background:] involves: 129P2/OlaHsd·MGI:3581421·Mus musculus
- Glb1tm1Jmat/Glb1tm1Jmat [background:] involves: C57BL/6 * CBA * ICR·MGI:3640134·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
4
Designations · no FDA orphan-indication approval yet
- EMA nizubaglustatTreatment of GM1 gangliosidosis · 28/06/2024 · PositiveEMA designation
- EMA Adeno-associated viral vector serotype rh.10 expressing beta-galactosidaseTreatment of GM1 gangliosidosis · 20/03/2017 · PositiveEMA designation
- EMA adeno-associated virus serotype hu68 containing the human GLB1 geneTreatment of GM1 gangliosidosis · 19/10/2020 · PositiveEMA designation
- EMA acetylleucineTreatment of GM1 gangliosidosis · 11/10/2022 · PositiveEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
15
Drugs / clinical candidates · MONDO_0018149
- NIZUBAGLUSTAT·phase 3
- VENGLUSTAT·phase 3
- ALEMTUZUMAB·phase 2
- CLOFARABINE·phase 2
- HYDROXYUREA·phase 2
- MELPHALAN·phase 2
- MYCOPHENOLATE MOFETIL·phase 2
- BOMTABEGAGENE BAVOPARVOVEC·phase 1 2
- DEOXYGALACTONOJIRIMYCIN·preclinical
- LEVACETYLLEUCINE·unknown
- LIXMABEGAGENE RELDUPARVOVEC·phase 1 2
- METHYLPREDNISOLONE·phase 1 2
- PREDNISONE·phase 1 2
- RITUXIMAB·phase 1 2
- SIROLIMUS·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
4,909
4,909 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
4,909 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,765 in the last 10 years · low confidence
Phrase hits: 2,426 · MeSH hits: 0
Who's working on it?
1,308
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Tifft CJ22 papers · 2026
Glycosphingolipid and Glycoprotein Disorders Unit, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States.
Papers in Europe PMC - 02Acosta MT15 papers · 2026
Undiagnosed Diseases Program, Common Fund, Office of the Director, National Institutes of Health, Bethesda, MD, United States.
Papers in Europe PMC - 03Johnston JM13 papers · 2026
Department of Genetics and Metabolism, Rare Disease Institute, Children's National Medical Center, Washington, DC, United States of America.
Papers in Europe PMC - 04Shazeeb MS12 papers · 2026
Department of Radiology, UMass Chan Medical School, Worcester, Massachusetts, USA.
Papers in Europe PMC - 05D'Souza P11 papers · 2026
Medical Genetics Branch and Office of the Clinical Director, NHGRI, NIH, Bethesda, MD 20892, USA; Office of the Clinical Director, NHGRI, NIH, Bethesda, MD, 20892, USA.
Papers in Europe PMC - 06Lewis CJ11 papers · 2026
Office of the Clinical Director, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Papers in Europe PMC - 07Vardar Z10 papers · 2026
Department of Radiology, UMass Chan Medical School, Worcester, Massachusetts, USA.
Papers in Europe PMC - 08Gahl WA9 papers · 2026
Medical Genetics Branch, National Human Genome Research Institute, 10 Center Drive, Bethesda, MD 20892, USA.
Papers in Europe PMC - 09Jiang X9 papers · 2026
Department of Medicine, Washington University School of Medicine, Saint Louis, MO, United States.
Papers in Europe PMC - 10Martin DR9 papers · 2026
Scott Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
9
interventional trials for this specific condition
9 interventional trials matched this specific condition name; 3 currently recruiting in our sample. 9 trials are registered for gangliosidosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 28 July 2026
9 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92th percentile).
low confidence · 92th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
9 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT03952637·RECRUITING·A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis
Not reviewed·Conditions: Lysosomal Diseases · Gangliosidosis · GM1·Matched via name phrase
- NCT07479953·NOT YET RECRUITING·Prenatal Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis Clinical Trial
Not reviewed·Conditions: GM1 Gangliosidoses · GM1 Gangliosidosis, Type I · GM1 Gangliosidosis, Type 2·Matched via name phrase
- NCT07054515·RECRUITING·A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
Not reviewed·Conditions: Niemann-Pick Type C Disease · GM1 Gangliosidosis · GM2 Gangliosidosis·Matched via name phrase
Broader category: gangliosidosis
9
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07399704·RECRUITING·A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
Not reviewed·Conditions: GM2 Gangliosidosis · Niemann-Pick Type C Disease·Matched via name phrase
Observational and natural-history studies
9 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05368038·ENROLLING BY INVITATION·ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Not reviewed·Conditions: Acid Sphingomyelinase Deficiency · Ceroid Lipofuscinosis, Neuronal, 2 · Cerebrotendinous Xanthomatosis · Fabry Disease·Matched via name phrase
- NCT06539169·RECRUITING·FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Not reviewed·Conditions: Alpha-Thalassemia · Beta-Thalassemia · Amyloidosis · Amyotrophic Lateral Sclerosis·Matched via name phrase
- NCT00668187·RECRUITING·A Natural History Study of the Gangliosidoses
Not reviewed·Conditions: Tay-Sachs Disease · Sandhoff Disease · Late Onset Tay-Sachs Disease · GM1 Gangliosidosis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for GM1 gangliosidosis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("GM1 gangliosidosis" OR "Beta-galactosidase-1 deficiency" OR "GLB1 deficiency" OR "Landing disease" OR "GM>1< gangliosidosis" OR "Landing syndrome" OR "gangliosidosis GM1") OR ("GLB1" OR "GLB1 syndrome" OR "GLB1-related" OR "GM1 syndrome" OR "GM1-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"GM1 gangliosidosis" OR "Beta-galactosidase-1 deficiency" OR "GLB1 deficiency" OR "Landing disease" OR "GM>1< gangliosidosis" OR "Landing syndrome" OR "gangliosidosis GM1"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 9 interventional · 9 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"gangliosidosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (4909) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T13:31:51.509Z
